| 1 |
28293479 | MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients. | 2017 Mar |
3 |
| 2 |
26779831 | Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. | 2016 Mar |
1 |
| 3 |
26931196 | Gender differences in multiple sclerosis epidemiology and treatment response. | 2016 Mar |
1 |
| 4 |
27366230 | Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. | 2016 Jul |
1 |
| 5 |
24009164 | Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. | 2014 Apr |
1 |
| 6 |
24444338 | Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. | 2014 Jul |
1 |
| 7 |
24586361 | Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. | 2014 |
1 |
| 8 |
24748646 | HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis. | 2014 Jun |
2 |
| 9 |
25208455 | Gender effects on treatment response to interferon-beta in multiple sclerosis. | 2014 Dec |
1 |
| 10 |
22976494 | Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. | 2012 Oct |
1 |
| 11 |
20610349 | Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. | 2010 Jul |
1 |
| 12 |
18727672 | Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent. | 2009 Jan |
1 |
| 13 |
18715196 | BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. | 2008 Sep |
1 |
| 14 |
17548434 | Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis. | 2007 Jun |
1 |
| 15 |
17619058 | IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. | 2007 Sep |
1 |
| 16 |
16241970 | Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. | 2005 Nov |
1 |
| 17 |
15045868 | [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis]. | 2004 |
3 |
| 18 |
15549353 | Optimising MS disease-modifying therapies: antibodies in perspective. | 2004 Sep |
6 |
| 19 |
11437159 | Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. | 2001 May |
1 |